• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

    5/5/22 8:30:00 AM ET
    $CPNG
    $GH
    $OZON
    $TXG
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical Specialities
    Health Care
    Get the next $CPNG alert in real time by email

    Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform

    Separately, Fanatics releases its first environmental, social and governance (ESG) report

    Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising and building some of the world's most influential tech companies and consumer brands.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005104/en/

    Lydia Jett (Photo: Business Wire)

    Lydia Jett (Photo: Business Wire)

    Both well-admired leaders will play vital roles in uncovering and amplifying opportunities for Fanatics to continue scaling its businesses worldwide, which currently include licensed merchandise and e-commerce, trading cards and collectibles, digital collectibles and NFT's, and online sports betting and iGaming.

    "Fanatics is in the midst of incredible transformation and the deep expertise and insight that Lydia and Jonathan both bring to the board will be vital as we unlock a new digital experience for sports fans globally," said Fanatics CEO Michael Rubin. "They are both visionaries in their respective fields that will provide invaluable support and guidance as we continue building a revolutionary sports platform."

    Lydia, the first female to hold the title of Managing Partner within SoftBank's Vision Fund, has nearly twenty years of experience investing in and serving on the boards of market leading technology businesses. Since SoftBank's initial backing of Fanatics in 2017 - when the firm led a more than $1 billion investment round - she has been a driving force behind the company's innovation across the licensed sports industry and recent expansion beyond merchandise.

    "Over my past five years with the Fanatics management team, I have seen an extraordinary focus, agility and creativity targeted towards fundamentally remaking an industry to better serve its ultimate customers: leagues, athletes and fans," said Jett. "As we enter the next half decade together, Fanatics is better positioned than ever to be a driving force behind improving a global sports fan's experience across the digital and physical world."

    Jonathan, a globally respected marketing and advertising professional, co-founded the influential brand building and marketing consultancy firm, TwentyFirstCenturyBrand, and serves as Executive Chairman. Mildenhall also previously served as CMO of Airbnb from 2014 to 2018, a time in which the company's valuation increased from $1 billion to more than $31 billion. Mildenhall's expertise is defining company purpose and values, brand strategy and digital transformation, assets that will be invaluable to Fanatics as the company continues to build its brand globally and unlock opportunities to engage with sports fans across current and emerging verticals.

    "Over the last six months I have gotten to know Michael, his executive team, and the Fanatics business in a deep and substantial way," said Mildenhall. "The deeper my understanding of the incredible opportunity ahead the more irresistible the idea of joining the board became. Fanatics will become a culturally significant global brand that will define this and further generations to come."

    In addition to Fanatics, both Lydia and Jonathan serve as members on several company boards. Jett has represented SoftBank on the boards of global internet, e-commerce and blockchain companies including Coupang (NYSE:CPNG), Flipkart, GoTo (IDX: GOTO) and Weee!, and Mildenhall serves on the board of Peloton, Northern Star SPAC, and GoFundMe.

    Separate from these board appointments, Fanatics recently released its first environmental, social and governance (ESG) report. The report, which spans 2020 and 2021, covers ESG efforts across several initiatives, including the company's customer-centric approach, philanthropic endeavours, Fanatics' inclusion, diversity, equity, and advocacy (IDEA) model, sustainability, labor and human rights, and much more.

    To read the full report: https://www.fanaticsinc.com/global-impact

    About Lydia Jett

    Lydia Jett is a Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA) where she has led and represented SoftBank on the Board of Directors of many of the firm's global investments in consumer internet, e-commerce and blockchain companies including: Coupang (NYSE:CPNG), Fanatics, Flipkart, GoTo (IDX: GoTo), LTK, Misfits Market, Pacaso, The Sandbox, Veho and Weee!

    Prior to SBIA, Lydia was a senior member of the investment team at SoftBank Group Corp International where she led SBGI's investments in Guardant Health (NASDAQ:GH) and 10X Genomics (NASDAQ:TXG). Previously, Lydia was a Vice President at M/C Partners, a growth equity firm, and an Associate at Goldman Sachs in the Principal Investment Area where she invested across media and technology sectors. She started her career at JPMorgan.

    In addition, Lydia is an independent board member of Ozon (NASDAQ:OZON), where she serves on the Audit, Compensation and Nomination and Governance Committees and has published work in Fast Company. Lydia is a graduate of the Stanford Graduate School of Business, the London School of Economics and Smith College, and has been recognized as one of Fortune's "Most Powerful Women."

    About Jonathan Mildenhall

    Jonathan Mildenhall co-founded TwentyFirstCenturyBrand, the influential brand-building and marketing consultancy firm, in 2018, and serves as the company's Executive Chairman. He is also a board member on several company boards, including Peloton, Northern Star SPAC, and GoFundMe, and he serves as the Co-Chair of non-profit College Track's Los Angeles Advisory Board. Prior to co-founding TwentyFirstCenturyBrand, Mildenhall served as CMO of Airbnb from 2014 to 2018, during which time Airbnb's valuation increased from $1 billion to more than $31 billion.

    Prior to Airbnb, Mildenhall led The Coca-Cola Company's marketing initiatives as VP of global advertising strategy and content excellence from 2007 to 2013, and as SVP of integrated marketing communication and design excellence from 2013 to 2014. Earlier in his career, Mildenhall served in various management positions in advertising. Mildenhall holds an HND in Business and Finance from The Manchester Metropolitan University. He completed the Advanced Management Program at Harvard Business School and holds an Honorary Doctorate in Business Administration from The Manchester Metropolitan University. Mildenhall lives in Los Angeles with his husband Mirco and their children Dominica and Oliver.

    He has been named to the Financial Times "EMpower 100 Ethnic Minority Leaders" list, has won the AdWeek Brand Genius award, and has been recognized on the Business Insider list of the "Top 50 Most Innovative CMOs in the World."

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005104/en/

    Get the next $CPNG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CPNG
    $GH
    $OZON
    $TXG

    CompanyDatePrice TargetRatingAnalyst
    Guardant Health Inc.
    $GH
    6/2/2026$150.00Outperform
    Wolfe Research
    Guardant Health Inc.
    $GH
    6/2/2026$160.00In-line → Outperform
    Evercore ISI
    Coupang Inc.
    $CPNG
    5/6/2026$23.00Buy → Hold
    Deutsche Bank
    Coupang Inc.
    $CPNG
    5/6/2026$22.20Buy → Neutral
    Citigroup
    10x Genomics Inc.
    $TXG
    3/31/2026Mkt Perform → Outperform
    William Blair
    Guardant Health Inc.
    $GH
    2/20/2026$125.00 → $135.00Buy
    Canaccord Genuity
    Guardant Health Inc.
    $GH
    2/17/2026$120.00Outperform
    Robert W. Baird
    Coupang Inc.
    $CPNG
    2/5/2026$17.00Underperform
    Bernstein
    More analyst ratings

    $CPNG
    $GH
    $OZON
    $TXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Guardant Health with a new price target

    Wolfe Research resumed coverage of Guardant Health with a rating of Outperform and set a new price target of $150.00

    6/2/26 8:33:51 AM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Guardant Health from In-line to Outperform and set a new price target of $160.00

    6/2/26 8:17:12 AM ET
    $GH
    Medical Specialities
    Health Care

    Coupang downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Coupang from Buy to Hold and set a new price target of $23.00

    5/6/26 8:45:26 AM ET
    $CPNG
    Catalog/Specialty Distribution
    Consumer Discretionary

    $CPNG
    $GH
    $OZON
    $TXG
    SEC Filings

    View All

    SEC Form 144 filed by Guardant Health Inc.

    144 - Guardant Health, Inc. (0001576280) (Subject)

    5/22/26 5:44:40 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 144 filed by Guardant Health Inc.

    144 - Guardant Health, Inc. (0001576280) (Subject)

    5/20/26 4:04:12 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 144 filed by Coupang Inc.

    144 - Coupang, Inc. (0001834584) (Subject)

    5/19/26 4:00:10 PM ET
    $CPNG
    Catalog/Specialty Distribution
    Consumer Discretionary

    $CPNG
    $GH
    $OZON
    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mehta Neil bought $136,562,971 worth of Class A Common Shares (7,350,104 units at $18.58) (SEC Form 4)

    4 - Coupang, Inc. (0001834584) (Issuer)

    3/13/26 9:04:18 PM ET
    $CPNG
    Catalog/Specialty Distribution
    Consumer Discretionary

    Director Greenoaks Capital Partners Llc bought $37,540,910 worth of Class A Common Shares (1,400,000 units at $26.81) (SEC Form 4)

    4 - Coupang, Inc. (0001834584) (Issuer)

    5/16/25 7:30:26 PM ET
    $CPNG
    Catalog/Specialty Distribution
    Consumer Discretionary

    Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    2/25/25 5:22:04 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $CPNG
    $GH
    $OZON
    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coupang Jumps to No. 132 on Fortune 500® as the Company Scales AI-Driven Global Commerce

    International expansion creates new opportunities for businesses, brands and customers across Coupang's global network Coupang, Inc., a U.S.-based technology leader, today was named to the Fortune 500® for the fourth consecutive year, jumping 10 places to No. 132 as it continues to grow and advance its innovative global fulfillment and logistics network. The Fortune 500® ranks the largest U.S. companies by total revenue each year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603035002/en/Coupang climbs 10 spots on the Fortune 500 to No. 132 Seattle-based Coupang generated $34.5 billion in revenue in 2025, an increase of 1

    6/3/26 12:00:00 PM ET
    $CPNG
    Catalog/Specialty Distribution
    Consumer Discretionary

    Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting

    New performance data demonstrates validity of Guardant360 Liquid CDx as a comprehensive pan-cancer companion diagnostic Findings show how Guardant360 Liquid CDx can expand access to targeted therapies by identifying actionable biomarkers missed by genomic testing Presentations reinforce Guardant's role advancing genomic and epigenomic profiling, characterizing tissue-free MRD and recurrence monitoring, and expanding biomarker-guided precision oncology Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing ad

    5/28/26 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    American Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

    Updated ACS guideline offers Shield as a new choice for over 50 million eligible Americans who are not up to date with their colorectal cancer screening Shield is the first and only FDA-approved blood test included in both ACS and NCCN guidelines Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield as a choice for patients who decline or have not completed stool-based or visual examination screening tests. In an effort to address persistent

    5/27/26 7:47:00 AM ET
    $GH
    Medical Specialities
    Health Care

    $CPNG
    $GH
    $OZON
    $TXG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

    For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

    5/28/21 1:05:48 PM ET
    $AMGN
    $GH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

    For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

    5/21/21 12:50:51 PM ET
    $JNJ
    $GH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $CPNG
    $GH
    $OZON
    $TXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Joyce Meghan V. exercised 10,000 shares at a strike of $38.05 and sold $1,269,809 worth of shares (10,000 units at $126.98) (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    6/4/26 6:07:18 PM ET
    $GH
    Medical Specialities
    Health Care

    Director Krognes Steve E. converted options into 154 shares, increasing direct ownership by 0.80% to 19,516 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    6/1/26 5:30:58 PM ET
    $GH
    Medical Specialities
    Health Care

    Director Hidalgo Medina Manuel sold $130,060 worth of shares (1,000 units at $130.06), decreasing direct ownership by 61% to 639 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    5/29/26 5:30:38 PM ET
    $GH
    Medical Specialities
    Health Care

    $CPNG
    $GH
    $OZON
    $TXG
    Leadership Updates

    Live Leadership Updates

    View All

    Alex M. Azar II Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention. "We're honored to welcome Secretary Azar to Guardant's board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Secretary Azar has served at the senior-most levels of government as well as th

    9/15/25 4:07:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

    Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release

    3/5/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Roberto A. Mignone Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look

    10/24/24 5:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $CPNG
    $GH
    $OZON
    $TXG
    Financials

    Live finance-specific insights

    View All

    Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

    First quarter 2026 revenue growth of 48% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.30 to $1.32 billion, representing growth of 32% to 34% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: Reported total revenue of $301.7 million, an increase of 48%, driven by: Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% Biopharma & Data revenue of $53.0 m

    5/7/26 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    10x Genomics Reports First Quarter 2026 Financial Results

    PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026. Recent Updates Revenue was $150.8 million for the first quarter of 2026, representing a 3% decrease over the corresponding period of 2025. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.Launched Atera, a new platform to redefine how biology is measured and understood.

    5/7/26 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Coupang Announces Results for First Quarter 2026

    Net Revenues of $8.5 billion, up 8% YoY and 8% on a constant currency basis Product Commerce Segment Net Revenues of $7.2 billion, up 4% YoY and 5% on a constant currency basis Developing Offerings Segment Net Revenues of $1.3 billion, up 28% YoY and 25% on a constant currency basis Coupang, Inc. (NYSE:CPNG) today announced financial results for its first quarter ended March 31, 2026. Q1 2026 Consolidated Highlights: Total net revenues were $8.5 billion, up 8% YoY on both a reported and constant currency basis. Gross profit was $2.3 billion, decreasing 1% YoY and flat on a constant currency basis. Gross profit margin was 27.0%, a decrease of 228 bps YoY. Operating (loss) in

    5/5/26 4:05:00 PM ET
    $CPNG
    Catalog/Specialty Distribution
    Consumer Discretionary

    $CPNG
    $GH
    $OZON
    $TXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/13/24 7:34:17 PM ET
    $GH
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Coupang Inc.

    SC 13G/A - Coupang, Inc. (0001834584) (Subject)

    11/12/24 4:30:29 PM ET
    $CPNG
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Coupang Inc.

    SC 13G/A - Coupang, Inc. (0001834584) (Subject)

    11/8/24 2:52:10 PM ET
    $CPNG
    Catalog/Specialty Distribution
    Consumer Discretionary